Medical College, Qingdao University, Qingdao, China.
Department of Pediatric Endocrinology and Genetic Metabolic Diseases, Qingdao Women and Children's Hospital, Qingdao, China.
Pharmacology. 2019;104(5-6):258-266. doi: 10.1159/000501631. Epub 2019 Jul 25.
Diabetic nephropathy (DN) is a chronic complication of diabetes, and thus the present investigation evaluates the nephroprotective effect of anemonin against streptozotocin (STZ)-induced DN rats. Diabetes was induced by intraperitoneal administration of STZ (50 mg/kg) on day 2 and 3 postnatal, and rats were kept as such for the duration of 12 weeks. Thereafter, rats were treated with anemonin 75 and 150 mg/kg per oral for the period 4 week which means between the period of 12-16 weeks. Effect of anemonin was estimated by determining the blood glucose, markers of nephropathy, and mediators of inflammation in the serum and activity of tumor necrosis factor-α (TNF-α)converting enzyme (TACE) in the kidney tissue of DN rats. Moreover, reverse transcriptase polymerase chain reaction and western blot assay were determined in the kidney tissue homogenate of DN rats. Histopathology study was done by Periodic acid-Schiff's and masson staining for the pathological changes and apoptosis of podocytes in the kidney tissue of DN rats. Moreover, production of reactive oxygen species (ROS) was estimated in the kidney tissue by 2',7'-dichlorofluorescein staining. Data of study reveal that anemonin significantly reduces (p < 0.01) the blood glucose and markers of renal injury in the serum and urine of DN rats. There was a reduction in the level of cytokines in the serum, and production of ROS and activity of TACE were reduced in the kidney tissue of the anemonin-treated group than in the DN group. Expression of iRhom-2, TACE, TNF-α, and inducible nitric oxide synthase protein and histopathology of kidney tissue were attenuated in the anemonin-treated group in DN rats. In conclusion, data of study reveal that treatment with anemonin ameliorates progression of renal injury by regulating TACE/iRhom-2 signaling pathway.
糖尿病肾病(DN)是糖尿病的一种慢性并发症,因此本研究评估了白头翁素对链脲佐菌素(STZ)诱导的糖尿病肾病大鼠的肾保护作用。糖尿病是在第 2 天和第 3 天腹腔注射 STZ(50mg/kg)诱导的,大鼠在整个 12 周内保持这种状态。此后,大鼠分别给予白头翁素 75 和 150mg/kg 口服治疗 4 周,即 12-16 周期间。通过测定糖尿病肾病大鼠血清中血糖、肾病标志物、炎症介质和肿瘤坏死因子-α(TNF-α)转化酶(TACE)的活性,来评估白头翁素的作用。此外,还测定了糖尿病肾病大鼠肾组织中的逆转录酶聚合酶链反应和western blot 分析。对糖尿病肾病大鼠肾组织进行过碘酸希夫(Periodic acid-Schiff's)和马松染色,观察病理变化和足细胞凋亡。此外,通过 2',7'-二氯荧光素染色测定肾组织中活性氧(ROS)的产生。研究数据表明,白头翁素能显著降低(p<0.01)糖尿病肾病大鼠血清和尿液中的血糖和肾损伤标志物。血清中细胞因子水平降低,肾组织中 ROS 产生和 TACE 活性降低。与糖尿病组相比,白头翁素治疗组大鼠肾组织中 iRhom-2、TACE、TNF-α和诱导型一氧化氮合酶蛋白的表达及肾组织的组织病理学均减弱。总之,研究数据表明,白头翁素通过调节 TACE/iRhom-2 信号通路改善了肾脏损伤的进展。